The Sonire Therapeutics ultrasound system is currently being studied for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to first-line chemotherapy.
In a multicenter study of over 370 women who had surgery for ovarian cystic lesions without acute symptoms, researchers found that 42 percent of the resected lesions were deemed to have an O-RADS ultrasound risk score of 2, which has less than a one percent chance of malignancy.
The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.
Providing automated TI-RADS classifications and worksheets, the new AI-enabled software may facilitate improved efficiency with thyroid ultrasound exams.